The primary challenge in finding drugs from nature has shifted. Initially, it was culturing microbes, then avoiding rediscovery of known molecules. Today, with advanced screening generating vast data, the bottleneck is prioritizing the most promising chemical hits for drug development.
A major failure point for natural products is late-stage toxicity. Novogaia mitigates this by simultaneously screening for bioactivity and analyzing chemical properties with mass spectrometry. This prioritizes active compounds that also have favorable drug-like characteristics from the very beginning, reducing downstream risk.
Mass spectrometry was traditionally used to identify known chemical compounds. AI models can now analyze vast, untargeted mass spec data to identify novel chemical structures. This elevates the technology from a simple detection tool to a powerful engine for new molecule discovery.
While Novogaia is building a next-gen discovery platform, CEO Tess Bevers emphasizes that the company's primary focus must be advancing its first drug candidates. For early-stage biotechs, the tangible value lies in getting molecules further down the pipeline, not just in perfecting the underlying technology.